You are here

Our science / Clinical Trials / Find a Trial / NCT00239928

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

Back to Search Print Save as PDF Bookmark Trial

NCT00239928

Last updated on February 23, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Nagoya, Aichi, Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
51 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- After completion of the preceding study (A5751010)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Serious heart, kidney and/or liver disease

- Diabetic retinopathy

NCT00239928
Pfizer
Completed
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Age Related Macular Degeneration
Retinal Pigment Epithelium Safety Study For Patients In B4711001
NCT03102138
All Genders
60+
Years
London,
Age-related Macular Degeneration
Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
NCT00787319
All Genders
18+
Years
Multiple Sites
Neovascular Age-related Macular Degeneration
Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
NCT00820742
All Genders
Neovascular Age-related Macular Degeneration
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
NCT00858208
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected].com

Call Now